Cargando…
Nucleolin Targeting by N6L Inhibits Wnt/β-Catenin Pathway Activation in Pancreatic Ductal Adenocarcinoma
SIMPLE SUMMARY: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that has no effective treatment. Nucleolin targeting by the pseudopeptide N6L inhibits the tumor growth and metastasis of pancreatic ductal adenocarcinoma (PDAC). Here, we explored the pathways regulated by nucleolin and...
Autores principales: | Raineri, Fabio, Bourgoin-Voillard, Sandrine, Cossutta, Mélissande, Habert, Damien, Ponzo, Matteo, Houppe, Claire, Vallée, Benoît, Boniotto, Michele, Chalabi-Dchar, Mounira, Bouvet, Philippe, Couvelard, Anne, Cros, Jerome, Debesset, Anais, Cohen, José L., Courty, José, Cascone, Ilaria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232280/ https://www.ncbi.nlm.nih.gov/pubmed/34203710 http://dx.doi.org/10.3390/cancers13122986 |
Ejemplares similares
-
Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression
por: Ponzo, Matteo, et al.
Publicado: (2022) -
Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 14, 4265
por: Ponzo, Matteo, et al.
Publicado: (2022) -
Nucleolin Aptamer N6L Reprograms the Translational Machinery and Acts Synergistically with mTORi to Inhibit Pancreatic Cancer Proliferation
por: Chalabi-Dchar, Mounira, et al.
Publicado: (2021) -
Multivalent cationic pseudopeptide polyplexes as a tool for cancer therapy
por: Diamantopoulou, Zoi, et al.
Publicado: (2017) -
Integrated analysis of mRNA and miRNA expression in HeLa cells expressing low levels of Nucleolin
por: Kumar, Sanjeev, et al.
Publicado: (2017)